{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:28Z","timestamp":1786982848283,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open access funding provided by Universit\u00e0 degli Studi di Padova within the CRUI-CARE Agreement."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Acromegaly is a rare chronic disease characterized by systemic comorbidity and reduced quality of life. Although achieving biochemical control has always been the primary goal of acromegaly therapy, recent evidence has shown that the traditional assessment does not adequately capture the complexity of symptoms and patients\u2019 perception. These findings result in the need to improve a fast decision-making process of the clinician, who should not only take into account biochemical\u2013instrumental criteria, but also patients\u2019 symptoms. With the aim of supporting the clinician in the diagnostic and therapeutic decision-making process several disease-specific tools have been developed. The aim of this review is to provide a description of the acromegaly-specific tools, presenting their main features, their application in daily practice, and their efficacy and utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of Medline\/PubMed, ISI-Web of Knowledge, and Google Scholar databases was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Specific instruments and questionnaires have recently been developed to assist clinicians in the assessment of acromegaly. These are either Patient-Reported Outcome tools, such as Acromegaly Quality of Life Questionnaire (AcroQoL) and Pain Assessment Acromegaly Symptom Questionnaire (PASQ), or Clinician-Reported Outcome tools, such as ACROSCORE, SAGIT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and Acromegaly Disease Activity Tool (ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ). Such tools are extremely flexible and, therefore, have been widely adopted by endocrinologists and other professionals, so much so that they have also been included as recommendations in the 2018 international guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Questionnaires and tools are useful in the management of acromegaly patients. They help clinicians evaluate patients\u2019 symptoms and could assist in the evaluation of disease activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-022-01782-x","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:03:31Z","timestamp":1648051411000},"page":"1823-1834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management"],"prefix":"10.1007","volume":"45","author":[{"given":"S.","family":"Camerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wennberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Adriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vettor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-5399","authenticated-orcid":false,"given":"F.","family":"Dassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01183-y","author":"G Preo","year":"2021","unstructured":"Preo G et al (2021) The role of the dentist and orthodontist in recognizing oro-facial manifestations of acromegaly: a questionnaire-based study. Pituitary. https:\/\/doi.org\/10.1007\/s11102-021-01183-y","journal-title":"Pituitary"},{"issue":"4","key":"1782_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1782_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","volume":"20","author":"AJ van der Lely","year":"2017","unstructured":"van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, J\u00f8rgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT\u00ae, a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692\u2013701. https:\/\/doi.org\/10.1007\/s11102-017-0835-5","journal-title":"Pituitary"},{"issue":"2","key":"1782_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","volume":"106","author":"LHA Broersen","year":"2021","unstructured":"Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577\u2013587. https:\/\/doi.org\/10.1210\/clinem\/dgaa868","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1782_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","volume":"22","author":"A Giustina","year":"2019","unstructured":"Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S (2019) Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT\u00ae validation study. Pituitary 22(5):476\u2013487. https:\/\/doi.org\/10.1007\/s11102-019-00977-5","journal-title":"Pituitary"},{"issue":"9","key":"1782_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1782_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/cen.12959","volume":"84","author":"N Prencipe","year":"2016","unstructured":"Prencipe N, Floriani I, Guaraldi F, Di Giacomo SV, Cannavo S, Arnaldi G, Berton A, Torri V, Spinello M, Arvat E, Ghigo E, Grottoli S (2016) ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. Clin Endocrinol (Oxf) 84(3):380\u2013385. https:\/\/doi.org\/10.1111\/cen.12959","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1782_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","volume":"57","author":"SM Webb","year":"2002","unstructured":"Webb SM, Prieto L, Badia X, Albareda M, Catal\u00e1 M, Gaztambide S, Lucas T, P\u00e1ramo C, Pic\u00f3 A, Lucas A, Halperin I, Obiols G, Astorga R (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251\u2013258. https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01597.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1782_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1210\/clinem\/dgaa750","volume":"106","author":"X Guo","year":"2021","unstructured":"Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H, Xing B, Zhang S, Dong D (2021) Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China. J Clin Endocrinol Metab 106(1):211\u2013225. https:\/\/doi.org\/10.1210\/clinem\/dgaa750","journal-title":"J Clin Endocrinol Metab"},{"key":"1782_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5363849","author":"J Gu","year":"2020","unstructured":"Gu J, Xiang S, He M, Wang M, Gu Y, Li L, Yin Z (2020) Quality of life in patients with acromegaly before and after transsphenoidal surgical resection. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2020\/5363849","journal-title":"Int J Endocrinol"},{"issue":"1","key":"1782_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cen.14309","volume":"94","author":"LE Dichtel","year":"2021","unstructured":"Dichtel LE, Kimball A, Yuen KCJ, Woodmansee W, Haines MS, Guan QX, Swearingen B, Nachtigall LB, Tritos NA, Sharpless JL, Kaiser UB, Gerweck AV, Miller KK (2021) Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol (Oxf) 94(1):58\u201365. https:\/\/doi.org\/10.1111\/cen.14309","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1782_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1530\/EC-20-0176","volume":"9","author":"S Roumeau","year":"2020","unstructured":"Roumeau S et al (2020) Assessment of oro-dental manifestations in a series of acromegalic patients, the AcroDent study\u2019. Endocr Connect 9(8):824\u2013833. https:\/\/doi.org\/10.1530\/EC-20-0176","journal-title":"Endocr Connect"},{"issue":"1","key":"1782_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12020-020-02306-4","volume":"69","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, J\u00f8rgensen JOL, van der Lely A-J, Janssen JAMJL, Muhammad A, Neggers SJCMM (2020) Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine 69(1):165\u2013174. https:\/\/doi.org\/10.1007\/s12020-020-02306-4","journal-title":"Endocrine"},{"issue":"4","key":"1782_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","volume":"23","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M et al (2020) An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary 23(4):347\u2013358. https:\/\/doi.org\/10.1007\/s11102-020-01038-y","journal-title":"Pituitary"},{"issue":"3","key":"1782_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1530\/EJE-19-0732","volume":"182","author":"TLC Wolters","year":"2020","unstructured":"Wolters TLC et al (2020) The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol 182(3):319\u2013331. https:\/\/doi.org\/10.1530\/EJE-19-0732","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1782_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/13696998.2017.1419960","volume":"21","author":"X Badia","year":"2018","unstructured":"Badia X, Trainer P, Biermasz NR, Tiemensma J, Carre\u00f1o A, Roset M, Forsythe A, Webb SM (2018) Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. J Med Econ 21(4):382\u2013389. https:\/\/doi.org\/10.1080\/13696998.2017.1419960","journal-title":"J Med Econ"},{"issue":"3","key":"1782_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/jim-2017-000570","volume":"66","author":"S Liu","year":"2018","unstructured":"Liu S et al (2018) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med 66(3):653\u2013660. https:\/\/doi.org\/10.1136\/jim-2017-000570","journal-title":"J Investig Med"},{"key":"1782_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"PJ Caron","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19:49\u2013157. https:\/\/doi.org\/10.1007\/s11102-015-0693-y","journal-title":"Pituitary"},{"issue":"1","key":"1782_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1530\/EJE-15-0228","volume":"173","author":"JM Felt","year":"2015","unstructured":"Felt JM et al (2015) Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. Eur J Endocrinol 173(1):37\u201342. https:\/\/doi.org\/10.1530\/EJE-15-0228","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1782_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11102-014-0583-8","volume":"18","author":"SHPP Roerink","year":"2015","unstructured":"Roerink SHPP et al (2015) Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly. Pituitary 18(3):366\u2013375. https:\/\/doi.org\/10.1007\/s11102-014-0583-8","journal-title":"Pituitary"},{"issue":"10","key":"1782_CR21","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJCMM Neggers","year":"2008","unstructured":"Neggers SJCMM, van Aken MO, de Herder WW, Feelders RA, Janssen JAMJL, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853\u20133859. https:\/\/doi.org\/10.1210\/jc.2008-0669","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1782_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2265.2007.02891.x","volume":"67","author":"AN Paisley","year":"2007","unstructured":"Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shale SM, Trainer PJ (2007) Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 67(3):358\u2013362. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02891.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1782_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12020-020-02424-z","volume":"70","author":"I Bernab\u00e9u","year":"2020","unstructured":"Bernab\u00e9u I et al (2020) Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. Endocrine 70(3):575\u2013583. https:\/\/doi.org\/10.1007\/s12020-020-02424-z","journal-title":"Endocrine"},{"issue":"3","key":"1782_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12020-019-02061-1","volume":"66","author":"A Wennberg","year":"2019","unstructured":"Wennberg A et al (2019) Sleep disorders and cognitive dysfunction in acromegaly. Endocrine 66(3):634\u2013641. https:\/\/doi.org\/10.1007\/s12020-019-02061-1","journal-title":"Endocrine"},{"issue":"2","key":"1782_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12020-019-02011-x","volume":"66","author":"TRL Lima","year":"2019","unstructured":"Lima TRL, Kasuki L, Gadelha M, Lopes AJ (2019) Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study. Endocrine 66(2):301\u2013309. https:\/\/doi.org\/10.1007\/s12020-019-02011-x","journal-title":"Endocrine"},{"issue":"11","key":"1782_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfma.2019.05.007","volume":"118","author":"FY Tseng","year":"2019","unstructured":"Tseng FY et al (2019) Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan Acromegaly Registry. J Formos Med Assoc 118(11):1488\u20131493. https:\/\/doi.org\/10.1016\/j.jfma.2019.05.007","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"1782_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11102-019-00966-8","volume":"22","author":"LM Fatti","year":"2019","unstructured":"Fatti LM et al (2019) Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. Pituitary 22(5):552\u2013560. https:\/\/doi.org\/10.1007\/s11102-019-00966-8","journal-title":"Pituitary"},{"key":"1782_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PRBM.S183950","volume":"12","author":"E Solomon","year":"2019","unstructured":"Solomon E et al (2019) Executive functioning and quality of life in acromegaly. Psychol Res Behav Manag 12:39\u201344. https:\/\/doi.org\/10.2147\/PRBM.S183950","journal-title":"Psychol Res Behav Manag"},{"issue":"5","key":"1782_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.5603\/EP.a2017.0044","volume":"68","author":"DM Szcze\u015bniak","year":"2017","unstructured":"Szcze\u015bniak DM et al (2017) Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity? Endokrynol Pol 68(5):524\u2013532. https:\/\/doi.org\/10.5603\/EP.a2017.0044","journal-title":"Endokrynol Pol"},{"issue":"6","key":"1782_CR30","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/cen.13331","volume":"86","author":"N Kyriakakis","year":"2017","unstructured":"Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) 86(6):806\u2013815. https:\/\/doi.org\/10.1111\/cen.13331","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1782_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ghir.2015.06.008","volume":"25","author":"CD Andela","year":"2015","unstructured":"Andela CD, Biermasz NR, Kaptein AA, Pereira AM, Tiemensma J (2015) More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. Growth Horm IGF Res 25(5):219\u2013226. https:\/\/doi.org\/10.1016\/j.ghir.2015.06.008","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"1782_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-14-0996","volume":"172","author":"J Tiemensma","year":"2015","unstructured":"Tiemensma J, Pereira AM, Romijn JA, Broadbent E, Biermasz NR, Kaptein AA (2015) Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. Eur J Endocrinol 172(5):583\u2013593. https:\/\/doi.org\/10.1530\/EJE-14-0996","journal-title":"Eur J Endocrinol"},{"key":"1782_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fendo.2014.00229","volume":"5","author":"VJ Geraedts","year":"2015","unstructured":"Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C (2015) Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life. Front Endocrinol 5:229. https:\/\/doi.org\/10.3389\/fendo.2014.00229","journal-title":"Front Endocrinol"},{"issue":"2","key":"1782_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/EC-14-0028","volume":"3","author":"AJ Varewijck","year":"2014","unstructured":"Varewijck AJ, van der Lely AJ, Neggers SJCMM, Lamberts SWJ, Hofland LJ, Janssen JAMJL (2014) In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocr Connect 3(2):85\u201392. https:\/\/doi.org\/10.1530\/EC-14-0028","journal-title":"Endocr Connect"},{"issue":"2","key":"1782_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-014-0166-5","volume":"47","author":"P Anagnostis","year":"2014","unstructured":"Anagnostis P et al (2014) Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine 47(2):564\u2013571. https:\/\/doi.org\/10.1007\/s12020-014-0166-5","journal-title":"Endocrine"},{"issue":"6","key":"1782_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11102-013-0544-7","volume":"17","author":"H Kepicoglu","year":"2014","unstructured":"Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P (2014) Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary 17(6):557\u2013563. https:\/\/doi.org\/10.1007\/s11102-013-0544-7","journal-title":"Pituitary"},{"issue":"6","key":"1782_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11102-013-0533-x","volume":"17","author":"R Mangupli","year":"2014","unstructured":"Mangupli R, Camperos P, Webb SM (2014) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17(6):495\u2013499. https:\/\/doi.org\/10.1007\/s11102-013-0533-x","journal-title":"Pituitary"},{"issue":"9","key":"1782_CR38","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00701-013-1809-7","volume":"155","author":"M Milian","year":"2013","unstructured":"Milian M, Honegger J, Gerlach C, Psaras T (2013) Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors\u2014a longitudinal study of 106 patients. Acta Neurochir (Wien) 155(9):1637\u20131645. https:\/\/doi.org\/10.1007\/s00701-013-1809-7","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"1782_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1507\/endocrj.EJ12-0424","volume":"60","author":"O Celik","year":"2013","unstructured":"Celik O, Hatipoglu E, Akhan SE, Uludag S, Kadioglu P (2013) Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center. Endocr J 60(6):753\u2013761. https:\/\/doi.org\/10.1507\/endocrj.EJ12-0424","journal-title":"Endocr J"},{"issue":"11","key":"1782_CR40","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1210\/jc.2011-1645","volume":"96","author":"J Tiemensma","year":"2011","unstructured":"Tiemensma J, Kaptein AA, Pereira AM, Smit JWA, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96(11):3550\u20133558. https:\/\/doi.org\/10.1210\/jc.2011-1645","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1782_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11102-011-0298-z","volume":"14","author":"S Cannav\u00f2","year":"2011","unstructured":"Cannav\u00f2 S et al (2011) Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. Pituitary 14(4):328\u2013334. https:\/\/doi.org\/10.1007\/s11102-011-0298-z","journal-title":"Pituitary"},{"issue":"1","key":"1782_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/BF03346555","volume":"33","author":"C Sardella","year":"2010","unstructured":"Sardella C et al (2010) Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 33(1):20\u201325. https:\/\/doi.org\/10.1007\/BF03346555","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1782_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ghir.2010.02.003","volume":"20","author":"MJE Wassenaar","year":"2010","unstructured":"Wassenaar MJE et al (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res 20(3):226\u2013233. https:\/\/doi.org\/10.1016\/j.ghir.2010.02.003","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"1782_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-07-0838","volume":"158","author":"A Miller","year":"2008","unstructured":"Miller A, Doll H, David J, Wass J (2008) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 158(5):587\u2013593. https:\/\/doi.org\/10.1530\/EJE-07-0838","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1782_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-07-0697","volume":"158","author":"MP Matta","year":"2008","unstructured":"Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH\/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305\u2013310. https:\/\/doi.org\/10.1530\/EJE-07-0697","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1782_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2265.2007.03169.x","volume":"69","author":"AA Van Der Klaauw","year":"2008","unstructured":"Van Der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf) 69(1):123\u2013128. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03169.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1782_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1530\/EJE-07-0356","volume":"157","author":"G T\u2019Sjoen","year":"2007","unstructured":"T\u2019Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly. Eur J Endocrinol 157(4):411\u2013417. https:\/\/doi.org\/10.1530\/EJE-07-0356","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1782_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2265.2005.02307.x","volume":"63","author":"R Trepp","year":"2005","unstructured":"Trepp R et al (2005) Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) 63(1):103\u2013110. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02307.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"1782_CR49","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s10198-021-01318-9","volume":"22","author":"K Wang","year":"2021","unstructured":"Wang K et al (2021) Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly. Eur J Health Econ 22(9):1381\u20131391. https:\/\/doi.org\/10.1007\/s10198-021-01318-9","journal-title":"Eur J Health Econ"},{"issue":"5","key":"1782_CR50","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11102-021-01153-4","volume":"24","author":"MF Arshad","year":"2021","unstructured":"Arshad MF, Ogunleye O, Ross R, Debono M (2021) Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study). Pituitary 24(5):768\u2013777. https:\/\/doi.org\/10.1007\/s11102-021-01153-4","journal-title":"Pituitary"},{"issue":"2","key":"1782_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/edm2.229","volume":"4","author":"D Ballesteros-Herrera","year":"2021","unstructured":"Ballesteros-Herrera D, Brise\u00f1o-Hern\u00e1ndez P, P\u00e9rez-Esparza R, Portocarrero-Ortiz LA (2021) Differences in quality of life between genders in acromegaly. Endocrinol Diabetes Metab 4(2):229. https:\/\/doi.org\/10.1002\/edm2.229","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"1782_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/BMR-200089","volume":"34","author":"SG de Alegria","year":"2021","unstructured":"de Alegria SG, Kasuki L, Gadelha M, Lopes AJ (2021) The Glittre Activities of Daily Living Test in patients with acromegaly: associations with hand function and health-related quality of life. J Back Musculoskelet Rehabil 34(3):441\u2013451. https:\/\/doi.org\/10.3233\/BMR-200089","journal-title":"J Back Musculoskelet Rehabil"},{"issue":"5","key":"1782_CR53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/ijem.IJEM_401_20","volume":"24","author":"B de Oliveira","year":"2020","unstructured":"de Oliveira B, A, et al (2020) Health-related quality of life in acromegaly patients: results from generic and disease-specific questionnaires. Indian J Endocrinol Metab 24(5):402\u2013405. https:\/\/doi.org\/10.4103\/ijem.IJEM_401_20","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"1782_CR54","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/clinem\/dgab536","volume":"106","author":"A Giustina","year":"2021","unstructured":"Giustina A et al (2021) International multicenter validation study of the SAGIT\u00ae\u00ae instrument in acromegaly. J Clin Endocrinol Metab 106(12):3555\u20133568. https:\/\/doi.org\/10.1210\/clinem\/dgab536","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1782_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000511811","volume":"111","author":"M Cellini","year":"2021","unstructured":"Cellini M et al (2021) Vertebral fractures associated with spinal SAGIT\u00aetal imbalance and quality of life in acromegaly: a radiographic study with EOS 2D\/3D technology. Neuroendocrinology 111(8):775\u2013785. https:\/\/doi.org\/10.1159\/000511811","journal-title":"Neuroendocrinology"},{"issue":"3\u20134","key":"1782_CR56","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000095532","volume":"83","author":"SM Webb","year":"2006","unstructured":"Webb SM (2006) Quality of life in acromegaly. Neuroendocrinology 83(3\u20134):224\u2013229. https:\/\/doi.org\/10.1159\/000095532","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1782_CR57","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12020-014-0521-6","volume":"49","author":"S Vandeva","year":"2015","unstructured":"Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S (2015) Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine 49(3):774\u2013782. https:\/\/doi.org\/10.1007\/s12020-014-0521-6","journal-title":"Endocrine"},{"issue":"2","key":"1782_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","volume":"155","author":"SM Webb","year":"2006","unstructured":"Webb SM, Badia X et al (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155(2):269\u2013277. https:\/\/doi.org\/10.1530\/eje.1.02214","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"1782_CR59","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177. https:\/\/doi.org\/10.1056\/NEJM200004203421604","journal-title":"N Engl J Med"},{"issue":"6","key":"1782_CR60","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","volume":"18","author":"C Sievers","year":"2015","unstructured":"Sievers C, Baur DM, Schwanke A, Buchfelder M, Droste M, Mann K, Stalla GK (2015) Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 18(6):916\u2013923. https:\/\/doi.org\/10.1007\/s11102-015-0673-2","journal-title":"Pituitary"},{"issue":"6","key":"1782_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11102-019-00986-4","volume":"22","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH, Haviv A, Mathias SD (2019) Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary 22(6):581\u2013593. https:\/\/doi.org\/10.1007\/s11102-019-00986-4","journal-title":"Pituitary"},{"key":"1782_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.627711","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front Endocrinol"},{"key":"1782_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00595-4","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. https:\/\/doi.org\/10.1186\/s12902-020-00595-4","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"1782_CR64","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23(2):140\u2013148. https:\/\/doi.org\/10.1007\/s11102-019-01013-2","journal-title":"Pituitary"},{"issue":"2","key":"1782_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11102-011-0302-7","volume":"15","author":"PW Rosario","year":"2012","unstructured":"Rosario PW, Calsolari MR (2012) Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary 15(2):179\u2013183. https:\/\/doi.org\/10.1007\/s11102-011-0302-7","journal-title":"Pituitary"},{"issue":"5","key":"1782_CR66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0030-1267912","volume":"119","author":"T Psaras","year":"2011","unstructured":"Psaras T, Honegger J, Gallwitz B, Milian M (2011) Are there gender-specific differences concerning quality of life in treated acromegalic patients? Exp Clin Endocrinol Diabetes 119(5):300\u2013305. https:\/\/doi.org\/10.1055\/s-0030-1267912","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"1782_CR67","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40618-016-0476-y","volume":"39","author":"F Guaraldi","year":"2016","unstructured":"Guaraldi F et al (2016) Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. J Endocrinol Invest 39(11):1277\u20131284. https:\/\/doi.org\/10.1007\/s40618-016-0476-y","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1782_CR68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11102-018-00933-9","volume":"22","author":"Y Jackson","year":"2019","unstructured":"Jackson Y, Flood E, Rhoten S, Janssen EM, Lundie M (2019) AcroVoice: eliciting the patients\u2019 perspective on acromegaly disease activity. Pituitary 22(1):62\u201369. https:\/\/doi.org\/10.1007\/s11102-018-00933-9","journal-title":"Pituitary"},{"issue":"1","key":"1782_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11102-015-0681-2","volume":"19","author":"A Giustina","year":"2016","unstructured":"The SAGIT Investigator Group, Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh X-MT, Sert C, Houchard A, Guillemin I, Melmed S (2016) SAGIT\u00ae: clinician-reported outcome instrument for managing acromegaly in clinical practice\u2014development and results from a pilot study. Pituitary 19(1):39\u201349. https:\/\/doi.org\/10.1007\/s11102-015-0681-2","journal-title":"Pituitary"},{"issue":"7","key":"1782_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jval.2014.08.754","volume":"17","author":"A Giustina","year":"2014","unstructured":"Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S, Truong TXM, Massien C, Dias-Barbosa C, Guillemin I, Arnould B, Melmed S (2014) SAGIT\u00a9: a novel clinician-reported outcome for managing acromegaly in clinical practice. Value Health 17(7):355. https:\/\/doi.org\/10.1016\/j.jval.2014.08.754","journal-title":"Value Health"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01782-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T09:55:24Z","timestamp":1662717324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01782-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01782-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review, no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}